Several prior studies have reported similar models incorporating variables such as tumor-infiltrating lymphocyte scores or tumor cellularity on day 15 of treatment, with these models having been found to predict patient outcomes after completion of neoadjuvant anti-HER2-based therapy33. Here, ERBB2 is linked to neoplasm.